AFP and hepatocellular carcinoma: Simultaneous assessment of gender, age, AFP, AFP-L3, and DCP, a panel denoted as GALAD score, in the same serum samples of 685 HCC patients showed that 55.8% were AFP-positive, 34.1% were AFP-L3-positive, and 54.2% were DCP-positive and the number of biomarkers present clearly reflected the extent of HCC and patient outcomes decreasing after treatment [96].